Elgeti, Thomas
Fröhlich, Matthias
Wismayer, Kim Kathrin
Tzschätzsch, Heiko
Hamm, Bernd
Sack, Ingolf
Schaafs, Lars-Arne
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EL 606-02)
Charité - Universitätsmedizin Berlin
Article History
Received: 20 September 2022
Accepted: 18 October 2022
First Online: 22 October 2022
Competing interests
: Bernd Hamm is a Grant Recipient of the Department of Radiology, Charité, and has further received funding from Abbott, AbbVie, Ablative Solutions, Accovion, Achaogen lnc., Actelion Pharmaceuticals, ADIR, Aesculap, AGO, AIF Arbeitsgemeinschaft industrieller Forschungsvereinigungen, AIO Arbeitsgemeinschaft lnternistische Onkologie, Alexion Pharmaceuticals, Amgen, AO Foundation, Arena Pharmaceuticals, art photonics GmbH Berlin, ASR Advanced sleep research, Astellas, AstraZeneca, BARD, Bayer Healthcare, Bayer Schering Pharma, Bayer Vital, BBraun, Berlin-Brandenburger Centrum für Regenerative Therapien (BCRT), Berliner Krebsgesellschaft, Biotronik, Bioven, BMBF Bundesministerium für Bildung und Forschung, Boehring Ingelheimer, Boston Biomedical Inc., BRACCO Group, Brainsgate, Bristol-Myers Squibb, Cascadian Therapeutics, lnc., Celgene, CELLACT Pharma, Celldex Therapeutics, CeIoNova BioSciences, Charité research organisation GmbH, Chiltern, CCovance, CUBIST, Curis, Daiichi, DC Devices, lnc. USA, Delcath Systems, Dermira lnc., Deutsche Krebshilfe, Deutsche Rheuma Liga, DFG, DSM Nutritional Products AG, Dt. Stiftung für Herzforschung, Dynavax, Eisai Ltd.‚ European Knowledge Centre, Mosquito Way, Hatfield, Eli Lilly and Company Ltd., EORTC, Epizyme, Inc., Essex Pharma, EU Programmes, Euroscreen S.A., Fibrex Medical Inc., Focused Ultrasound Surgery Foundation, Fraunhofer Gesellschaft, Galena Biopharma, Galmed Research and Development Ltd., Ganymed, GE, Genentech. Inc., GETNE (Grupo Español de Tumores Neuroendocrinos), Gilead Sciences, Inc., Glaxo Smith Kline, Glycotope GmbH, Berlin, Goethe Uni Frankfurt, Guerbet, Guidant Europe NV, Halozyme, Holaira Inc., ICON (CRO), Immunomedics Inc., Immunocore, Incyte, INC Research, Innate Pharma, InSightec Ltd., Inspiremd, inVentiv Health Clinical UK Ltd., Inventivhealth, IOMEDICO, IONIS, IPSEN Pharma, ISA Therapeutics, lsis Pharmaceuticals Inc., ITM Solution GmbH, Jansen, Kantar Health GmbH (CRO), Karyopharm Therapeutics, Inc., Kendle/MorphoSys AG, Kite Pharma, La Roche, Land Berlin, Lilly GmbH, Lion Biotechnology, Lombard Medical, Loxo Oncology, lnc, LSK BioPartners; USA, Lundbeck GmbH, LUX Biosciences, LYSARC, MacroGenics, MagForce, Medlmmune lnc., Medlmmune Limited, Medpace, Medpace Germany GmbH (CRO), MedPass (CRO), Medro-nic, Merck, Merrimack Pharmaceuticals lnc, MeVis Medical Solutions AG, Millennium Phar-maceuticals Inc., Mologen, MSD Sharp, NeoVacs SA, Nexus Oncology, Novartis, novocure, Nuvisan, Ockham oncology, Orion Corporation Orion Pharma, Parexel CRO Service, Perceptive, Pfizer GmbH, Pharma Mar, Pharmaceutical Research Associates GmbH (PRA), Pharmacyclics Inc., Philipps, PIQUR Therapeutics Ltd., Pluristem, Portola Pharmaceuticals, PPD (CRO), PRAint, Premier-research, Provectus Biopharmaceuticals, Inc., psicro, Pulmonx International Sàrl, Quintiles Gmbh, Respicardia, Roche, Samsung, Sanofi, sanofis-aventis S.A, Schumacher GmbH, Seattle Genetics, Servier (CRO), SGS Life Science Services (CRO), Siemens, Silena Therapeutics, Spectranetics GmbH, Spectrum Pharmaceuticals, St. Jude Medical, Stiftung Wolfgang Schulze, Symphogen, Taiho Pharmaceutical Co., Taqu Therapeutics Ltd., Terumo Medical Corporation, Tesaro, TETEC AG, TEVA, Theorem, Theradex, Threshold Pharmaceuticals Inc., TNS Healthcare GmbH, Toshiba, UCB Pharma, Uni München, VDI/VDE, Winicker Norimed, Wyeth Pharma, Xcovery Holding Company, and Zukunftsfond Berlin (TSB). The remaining authors declare no conflict of interest.